United Therapeutics Points To Pluristem's PLX-PAD As Its Most Transformative Product
- United Therapeutics brings Pluristem to the next level of clinical trials.
- PAH is an insidious disease with few treatment options.
- United Therapeutics' CEO called Pluristem's offering the "most transformative" of its products in Phase I.
- The only fully-automated manufacturing process validated by many regulatory bodies makes Pluristem a strong draw for partners.
- Pluristem is still at an early stage of clinical trials; larger studies may not give comparable results.